Dani Paul Bolognesi
Chief Executive Officer at B3 Bio, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Igor B. Roninson | M | - |
Senex Biotechnology, Inc.
 Senex Biotechnology, Inc. BiotechnologyHealth Technology Senex Biotechnology, Inc. is a drug discovery and development company focused on oncology therapeutics. The company was founded by Igor B. Roninson and is headquartered in Columbia, SC. | - |
| Robert R. Bonczek | M | - |
Senex Biotechnology, Inc.
Senex Biotechnology, Inc. BiotechnologyHealth Technology Senex Biotechnology, Inc. is a drug discovery and development company focused on oncology therapeutics. The company was founded by Igor B. Roninson and is headquartered in Columbia, SC.
Istari Oncology, Inc.
 Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | - |
| Dennis I. Goldberg | M | - |
Senex Biotechnology, Inc.
Senex Biotechnology, Inc. BiotechnologyHealth Technology Senex Biotechnology, Inc. is a drug discovery and development company focused on oncology therapeutics. The company was founded by Igor B. Roninson and is headquartered in Columbia, SC. | - |
| Sean Nolan | M | 56 |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | 6 years |
| Victor Sandor | M | 57 |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | 5 years |
| Richard L. Davidson | M | - |
Senex Biotechnology, Inc.
Senex Biotechnology, Inc. BiotechnologyHealth Technology Senex Biotechnology, Inc. is a drug discovery and development company focused on oncology therapeutics. The company was founded by Igor B. Roninson and is headquartered in Columbia, SC. | - |
| Raymond Cheong | M | 42 |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | 6 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Andrew L. Graham | M | - |
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Timothy J. Creech | M | 63 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Richard A. Franco | M | 82 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 3 years |
| M. Ross Johnson | M | 79 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 4 years |
| Steven Skolsky | M | 68 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 2 years |
| Carol-Ann Ohmstede | M | 68 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | - |
| E. Gary Cook | M | 79 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Julian Baker | M | 57 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Kevin Tang | M | 57 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Felix Baker | M | 55 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 7 years |
| Walter Capone | M | 59 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 5 years |
| Michael A. Recny | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 12 years |
| Michael Alrutz | M | 54 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 9 years |
| Lori Nembirkow | F | 50 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 6 years |
| Samuel Hopkins | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 6 years |
| Diego Miralles | M | 62 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 5 years |
| Myung-Cheol Kang | M | - |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 8 years |
| Charlie Sanders | M | 91 |
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | 10 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 25 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Dani Paul Bolognesi
- Personal Network
